TETRAPHASE PHARMACEUTICALS INC
TTPH evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for TTPH—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Mar 31, 2020.
Tracking 3 pipeline candidates · 4 clinical trials · 1 FDA decision for TETRAPHASE PHARMACEUTICALS INC.
Run TETRAPHASE PHARMACEUTICALS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available TETRAPHASE PHARMACEUTICALS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
7.3 months
D/E 0.36
Lead: Approved
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Frequently asked questions
What is TETRAPHASE PHARMACEUTICALS INC's lead drug candidate?
TETRAPHASE PHARMACEUTICALS INC's most advanced tracked candidate is tp-271 (Phase 1) for respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia.
What therapeutic areas does TETRAPHASE PHARMACEUTICALS INC focus on?
TETRAPHASE PHARMACEUTICALS INC develops therapies across Oncology, Infectious Disease, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.